These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29932973)

  • 21. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
    Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
    Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blocking CDK1/PDK1/β-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma.
    Wu CX; Wang XQ; Chok SH; Man K; Tsang SHY; Chan ACY; Ma KW; Xia W; Cheung TT
    Theranostics; 2018; 8(14):3737-3750. PubMed ID: 30083256
    [No Abstract]   [Full Text] [Related]  

  • 23. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
    Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
    Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activator of thyroid and retinoid receptor increases sorafenib resistance in hepatocellular carcinoma by facilitating the Warburg effect.
    Ma L; Liu W; Xu A; Ji Q; Ma Y; Tai Y; Wang Y; Shen C; Liu Y; Wang T; Han J; Zhao C
    Cancer Sci; 2020 Jun; 111(6):2028-2040. PubMed ID: 32279388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic effects of Rhizoma Paridis and Rhizoma Curcuma longa on different animal tumor models.
    Liu Z; Gao W; Man S; Zhang Y; Li H; Wu S; Zhang J; Liu C
    Environ Toxicol Pharmacol; 2014 Jul; 38(1):31-40. PubMed ID: 24873749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
    Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
    J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
    Huang M; Chen C; Geng J; Han D; Wang T; Xie T; Wang L; Wang Y; Wang C; Lei Z; Chu X
    Cancer Lett; 2017 Jul; 398():12-21. PubMed ID: 28377178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
    Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y
    PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emodin Sensitizes Hepatocellular Carcinoma Cells to the Anti-Cancer Effect of Sorafenib through Suppression of Cholesterol Metabolism.
    Kim YS; Lee YM; Oh TI; Shin DH; Kim GH; Kan SY; Kang H; Kim JH; Kim BM; Yim WJ; Lim JH
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30321984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination treatment with Rhizoma Paridis and Rhizoma Curcuma longa extracts and 10-hydroxycamptothecin enhances the antitumor effect in H22 tumor model by increasing the plasma concentration.
    Liu Z; Li H; Fan Y; Liu Y; Man S; Yu P; Gao W
    Biomed Pharmacother; 2016 Oct; 83():627-634. PubMed ID: 27459119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
    Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.
    Hsu C; Lin LI; Cheng YC; Feng ZR; Shao YY; Cheng AL; Ou DL
    Clin Cancer Res; 2016 May; 22(10):2555-64. PubMed ID: 26603262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor and antimetastatic activities of Rhizoma Paridis saponins.
    Man S; Gao W; Zhang Y; Yan L; Ma C; Liu C; Huang L
    Steroids; 2009; 74(13-14):1051-6. PubMed ID: 19699217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma.
    Tomonari T; Takeishi S; Taniguchi T; Tanaka T; Tanaka H; Fujimoto S; Kimura T; Okamoto K; Miyamoto H; Muguruma N; Takayama T
    Oncotarget; 2016 Feb; 7(6):7207-15. PubMed ID: 26769852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Global metabolic profiling for the study of Rhizoma Paridis saponins-induced hepatotoxicity in rats.
    Man S; Qiu P; Li J; Zhang L; Gao W
    Environ Toxicol; 2017 Jan; 32(1):99-108. PubMed ID: 26590097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells.
    Tang S; Tan G; Jiang X; Han P; Zhai B; Dong X; Qiao H; Jiang H; Sun X
    Oncotarget; 2016 Nov; 7(45):73257-73269. PubMed ID: 27689326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor activity of the microtubule inhibitor MBRI-001 against human hepatocellular carcinoma as monotherapy or in combination with sorafenib.
    Deng M; Li L; Zhao J; Yuan S; Li W
    Cancer Chemother Pharmacol; 2018 May; 81(5):853-862. PubMed ID: 29532153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Chen KF; Chen HL; Tai WT; Feng WC; Hsu CH; Chen PJ; Cheng AL
    J Pharmacol Exp Ther; 2011 Apr; 337(1):155-61. PubMed ID: 21205925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Valproic acid overcomes sorafenib resistance by reducing the migration of Jagged2-mediated Notch1 signaling pathway in hepatocellular carcinoma cells.
    Liu J; Yang X; Liang Q; Yu Y; Shen X; Sun G
    Int J Biochem Cell Biol; 2020 Sep; 126():105820. PubMed ID: 32750425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.